ZG16B: A New Tumor Biomarker Offers Important Insights for Drug Development in Pancreatic Cancer!ZG16B has recently emerged as a novel oncogene based on comprehensive bioinformatics analysis. Apparently, treatment of malignancies has experienced immense progress through immunotherapy. But the success of immunotherap...
Detailed information

Proteolysis Targeting Chimera (PROTAC): A "Revolutionary" Technology in Small Molecule Drug Discovery!Today, progress is widely being made in targeted cancer therapy. Most current drug targets are G-protein coupled receptors, nuclear receptors, ion channels or enzymes. Nevertheless, up to 80% of proteins remain “undrug...
Detailed information

How to Validate An Antibody？With the progress of science and medicine, antibodies have become potent tools to recognize, detect, isolate, or visualize their corresponding antigens in basic science research and clinical assays. Whether antibodies wo...
Detailed information

RSPO1: The key factor determining "battle of the sexes " is “favored” in the culture of organoids?Gender is much more complicated than it seems. There is increasing evidence that gender is not a simple dualism. For years, scientists have believed that female development is the default process, while male development ...
Detailed information

DDR1: a Novel Member of the RTKs Family, a Potential Target for Tumor Therapy!DDR1 has been newly identified as a member of the receptor tyrosine kinases (RTKs) family. It is widely recognized that RTKs control cell proliferation and differentiation, which are involved in tumorigenesis. Therefore,...
Detailed information

CLDN9: Another Key Regulator for Tumors or Hearing Loss from the CLDN Family!Presently, ample research suggested that CLDN family members are partly responsible for the development and progression of various malignancies, making them promising target candidates for cancer therapy. For example, CL...
Detailed information

CLDN6: A "New Favorite" in Targeted Cancer Therapy after CLDN 18.2!In September 2024, Daiichi Sankyo announced the Phase I clinical trial results of DS-9606, an antibody-drug conjugate (ADC) targeting Claudin-6 (CLDN6) developed based on an ADC platform. In the dose-escalation phase of ...
Detailed information

Recombinant Monkeypox Virus Proteins - Accelerate Monkeypox ResearchThe World Health Organization (WHO) declared the 2022 monkeypox outbreak a Public Health Emergency of International Concern (PHEIC) on 23 July 2022 local time [1]. On July 27, the WHO reported more than 18,000 cases of m...
Detailed information

SSTR2: A Prominent Target in SSTR Family, Offers a More Precise Therapy in Neuroendocrine Tumors (NET)Recently, Sanofi invested $20 million to gain priority negotiation rights for Zucara Therapeutics' novel SSTR2-targeting drug candidate ZT-01 for type 1 diabetes. ZT-01, an SSTR2 receptor antagonist, could prevent hypogl...
Detailed information

SEMA4D/CD100: As an Important Immunoregulator to Improve ImmunotherapyIn April 2022, the American Association for Cancer Research (AACR) annual meeting announced phase 1b/2 clinical data (NCT04815720) for Pepinemab, the first SEMA4D-targeted antibody for the treatment of recurrent or metas...
Detailed information